Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma by Chu, Sheng-Hua et al.
Promoter methylation and downregulation of
SLC22A18 are associated with the development
and progression of human glioma
Chu et al.
Chu et al. Journal of Translational Medicine 2011, 9:156
http://www.translational-medicine.com/content/9/1/156 (21 September 2011)RESEARCH Open Access
Promoter methylation and downregulation of
SLC22A18 are associated with the development







2 and Pu-Cha Jiang
2
Abstract
Background: Downregulation of the putative tumor suppressor gene SLC22A18 has been reported in a number of
human cancers. The aim of this study was to investigate the relationship between SLC22A18 downregulation,
promoter methylation and the development and progression of human glioma.
Method: SLC22A18 expression and promoter methylation was examined in human gliomas and the adjacent
normal tissues. U251 glioma cells stably overexpressing SLC22A18 were generated to investigate the effect of
SLC22A18 on cell growth and adherence in vitro using the methyl thiazole tetrazolium assay. Apoptosis was
quantified using flow cytometry and the growth of SLC22A18 overexpressing U251 cells was measured in an in vivo
xenograft model.
Results: SLC22A18 protein expression is significantly decreased in human gliomas compared to the adjacent
normal brain tissues. SLC22A18 protein expression is significantly lower in gliomas which recurred within six months
after surgery than gliomas which did not recur within six months. SLC22A18 promoter methylation was detected in
50% of the gliomas, but not in the adjacent normal tissues of any patient. SLC22A18 expression was significantly
decreased in gliomas with SLC22A18 promoter methylation, compared to gliomas without methylation. The
SLC22A18 promoter is methylated in U251 cells and treatment with the demethylating agent 5-aza-2-deoxycytidine
increased SLC22A18 expression and reduced cell proliferation. Stable overexpression of SLC22A18 inhibited growth
and adherence, induced apoptosis in vitro and reduced in vivo tumor growth of U251 cells.
Conclusion: SLC22A18 downregulation via promoter methylation is associated with the development and
progression of glioma, suggesting that SLC22A18 is an important tumor suppressor in glioma.
Background
Gliomas are a major class of human intrinsic brain
tumors, which includes well differentiated low grade
astrocytomas, anaplastic astrocytomas and glioblastoma
multiforme, the most malignant brain tumor of adult-
hood. Although resection remains the most effective
treatment for glioma, the high rate of postoperative
recurrence inevitably leads to a poor clinical outcome. In
an effort to develop novel potential effective treatments,
recent studies have focused on understanding the mole-
cular pathogenesis of glioma formation and progression.
Gliomas are frequently characterized by invasion and
growth [1] and are hypothesized to form in a multistage
process resulting from the accumulation of genetic
changes, including p53 and PTEN inactivation [2] and
activation of hypoxia-inducible factor 1a,V E G F[ 3 ]a n d
c-Met [4].
Solute carrier family 22 (organic cation transporter)
member 18 (SLC22A18), also known as IMPT1/BWR1A/
TSSC5, is located within the human 11p15.5 cluster [5,6].
Blast homology analysis suggests that SLC22A18 is a
member of the family of polyspecific transporters and
multidrug resistance genes [6]. More recently, SLC22A18
has been shown to be a tumor suppressor candidate and
a substrate for RING105 [7]. Structural mutations in
SLC22A18 are rare, with isolated reports of point muta-
tions in a breast cancer cell line, a rhabdomyosarcoma
cell line [6], and Wilms’ tumors and lung tumors [5].
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zygosity in hepatoblastomas [8] have also been reported,
indicating that SLC22A18 may play a role in tumorigen-
esis. In the current study, we sought to determine the
functional role of SLC22A18 in gliomas, in order to
define the relationship between SLC22A18,p r o m o t e r
methylation and tumor behavior.
Methods
Patients and specimens
Sixty surgically resected human glioma specimens and
the corresponding adjacent normal brain tissues were
collected at the Department of Neurosurgery, Zhongnan
Hospital of Wuhan University between 2004 and 2005
and the NO.3 People’s Hospital Affiliated to Shanghai
Jiao Tong University School of Medicine between 2006
and 2008. Informed patient consent and prior approval
from the Zhongnan Hospital of Wuhan University and
NO.3 People’s Hospital Affiliated to Shanghai Jiao Tong
University School of Medicine Ethics Committees (Ethic
approval ZNHWHU0387, NTPHSHJTUSM045) was
obtained before the clinical materials were used for
research purposes. All experiments on humans in the
present study were performed in compliance with the
Helsinki Declaration. All tumor specimens were patholo-
gically confirmed as glioma. Thirty specimens diagnosed
as low grade (WHO I-II) glioma and 30 diagnosed as
high grade (WHO III-IV) glioma were chosen for com-
parison. Of the 60 patients, 45 patients were male and 15
were female, with an age range of 28-58 years (average
43.4 years). All specimens were stored at -80°C until
analysis.
Immunostaining
Adult mouse brain was frozen in Tissuetek, and 6-10 μm
sections were cut using a cryostat. The sections were fixed
in methanol at -20°C for 10 min, washed and blocked with
0.1% BSA in PBS and the sections were sequentially incu-
bated with primary antibody (1 hr), the biotinylated sec-
ondary avidin-biotin complex (Vector Laboratories,
Burlingame, CA, USA) and diaminobenzidine substrate
(Sigma, St. Louis, MO, USA). After washing, the sections
were counterstained with methyl green and mounted in
Permount (Fluka, Buchs, Switzerland).
For immunostaining of cultured cells, cells were fixed for
10 min in methanol at -20°C, washed with PBS, blocked
with 0.1% BSA, stained with primary antibody followed by
a rhodamine- or fluorescein-conjugated secondary anti-
body and mounted in Vectashield (Vector Laboratories).
The antibodies used were SMI312 (Sternberger Monoclo-
nals, Baltimore, MD, USA) which is a cocktail of monoclo-
nal antibodies directed against phosphorylated epitopes on
the M and H neurofilament (NF) subunits Anti-b-tubulin
III monoclonal antibody (Sigma), anti-HA tag monoclonal
antibody 16B12 (Babco, Richmond, CA, USA), anti-GalC
and anti-GFAP monoclonal antibodies (Boehringer Man-
nheim GmbH, Mannheim, Germany), anti-p27
Kip1 mono-
clonal (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
and anti-b-tubulin monoclonal antibodies (Sigma and
Boehringer Mannheim) which gave similar results. The
secondary antibodies were obtained from Jackson Immu-
noResearch (West Grove, PA, USA).
Cell culture and cell growth
U251 cells (Wuhan University of China), human astro-
cytes, oligodendrocytes and neurons (ScienCell Research
Laboratories, San Diego, CA, USA) were cultured in
RPMI-1640 (Gibco Life Technologies, Paisley, Scotland,
UK) supplemented with 10% fetal bovine serum and peni-
cillinstreptomycin. To establish U251 cell growth curves,
1×1 0
4 cells were seeded in 6 cm diameter plates, and the
media was changed every three days. The plates were
divided into two groups (n = 9 each) and one was cultured
in RPMI-1640, while the other group was cultured in
RPMI-1640 containing 2 μM 5-aza-2-deoxycytidine. The
cell numbers were counted on days 3, 5 and 7 after seed-
ing. After counting, the cells from each group were subject
to Western blotting. The optimal concentration of the
demethylation agent had previously been determined by
culturing U251 cells in 0, 1, 2, 4, 8, 10, 20 and 40 μmol/ml
5-aza-2-deoxycytidine and 2 μM was chosen as the highest
concentration at which cells survived without drug-related
cell death observed in the culture.
Construction of the SLC22A18 expression vector
The 890 base pair SLC22A18 cDNA was amplified using
reverse transcription polymerase chain reaction (RT-PCR)
[9]. The PCR reaction (10 μl) contained 1 μlc D N A ,lμl
10 × buffer (MgCl2), 0.4 mM dNTPs, 1 umol primer, 1 U
TaqDNA Polymerase. After denaturation at 95°C for
5m i n ,P C Rw a sp e r f o r m e df o r3 5c y c l e s( 3 0sa t9 5 ° C ,
30 s at 50°C and 30 s at 72°C) and extended at 72°C for
5 min. The linear NHeI-EcoRI fragment containing the
SLC22A18 cDNA was subcloned into pcDNA3.1 (Invitro-
gen Company), which yielded pcDNA3.1-SLC22A18 by
T4 ligase (TaKaRa Company). The insertion of SLC22A18
in pcDNA3.1 was confirmed by PCR, restriction enzyme
digestion analysis (NHeI and EcoRI) and DNA sequencing.
Determination of the optimal concentration of G418
G418 is an aminoglycoside which is commonly used as a
selective agent for the bacterial neoR/kanR genes. U251
cells were incubated at 37°C in RPMI-1640 medium sup-
plemented with 10% calf serum, 100 u/ml penicillin and
100 μg/ml streptomycin, in an atmosphere of 5% CO2 at
saturated humidity. The culture medium was changed
every 48 h. The optimal concentration of G418 was
determined by plating U251 cells at 5 × 10
4 per well in
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50, 100, 150, 200, 300, 400, 500, 600, 700 or 800 μg/ml
and the culture media were changed every 48 h. The low-
est G418 concentration, at which all cells died after 12-14
days culture was chosen as the optimal concentration for
selection of resistance.
Transfection of U251 cells with pcDNA3.1-SLC22A18 and
PCR confirmation of SLC22A18 expression in U251 cells
To stably transfect the SLC22A18 gene, 1 × 10
6 U251 cells
were plated in 6 well plates 24 h before transfection and
lipofectamine 2000 (Invitrogen Company) was used to
transfect 5.0 μg of pcDNA3.1-SLC22A18 or 5.0 μgo f
empty pcDNA3.1 according to the manufacture’s instruc-
tions. After 48 h, the transfected cells were selected in
media supplemented containing 150 μg/ml G418 and the
media was changed every 48 h. Non-transfected U251
cells died within two weeks. G418-resistant pcDNA3.1-
SLC22A18 transfected cells were named U251-SLC22A18
and G418-resistant cells transfected pcDNA3.1 were
named as U251-EV.
To confirm the stable transfection of SLC22A18, DNA
from untransfected U251 cells, U251-EV and U251-
SLC22A18 cells was isolated using the Puregene™ DNA
Isolation Kit (Gentra systems, Minneapolis, MN, USA).
Primers were designed against SLC22A18 [10], forward
(5’- AGCTGAGCAGCCACTTCTC -3’)a n dr e v e r s e( 5 ’-
AAAGCTGCGGTACAGGAGG -3’)a n dP C Rw a sp e r -
formed in 50 μl reactions containing 3 μlc D N A ,5μl
10 × Buffer, 4 μl MgC12, 1 μld N T P s ,1μlp r i m e r sa n d
0.3 μl Taq DNA Polymerase with an initial denaturation
step of 94°C for 7 min, followed by 30 cycles of a three-
step program of 94°C for 30 s, 56°C for 30 s and 72°C
for 45 s, followed by a final extension step at 72°C for
7 min. The PCR products were electrophoresed on an
agarose gel.
Measurement of cell growth
Cell proliferation was measured using the methyl thiazole
tetrazolium (MTT) assay [11]. Cells were seeded in 24-
well plates at a density of 1 × 10
4 cells/well and 24 hr later
200 μl5m g / μl MTT (Sigma) in PBS was added to each
well incubated for 4 h at 37°C and the precipitate was
solubilized in 100 μl 100% dimethylsulfoxide (Sigma) with
shaking for 15 min. Absorbance values were determined
using an enzyme-linked immunosorbent assay reader
(Model 318, Shanghai, China) at 540 nm. Each assay was
performed nine times and the results are expressed as the
mean ± SE compared to the control.
Measurement of apoptosis by flow cytometry
U251 cells were centrifuged 72 hr after transfection after
transfection washed with PBS fixed in 7% cold ethanol
treated with 10 g/L RNase resuspended and stained with
10 g/L propidium iodine. After 30 min at room tempera-
ture in the dark, the cells were analyzed by scanning flow
cytometer to determine the percentage of apoptotic cells,
defined as cells in the cell cycle distribution with a lower
DNA content than G1 cells.
Adhesion assay
Cells were seeded in quadruplicate at a density of 1 ×
10
4 cells/well in 96 well plates coated with 10 g/L BSA,
50 mg/L Matrigel, or 10 mg/L fibronectin (Fn), cultured
at 37°C for 60 min, and the MTT assay was performed
as previously described [12-15]. Each assay was per-
formed in triplicate.
Tumor cell adherence to ECV304
ECV304 cells were plated in 96 well plates at a density of
5×1 0
4 cells/well cultured for 48 hr, the supernatant was
aspirated and U251, U251-EV or U251-SLC22A18 cells
were plated at a density of 5 × 10
4 cells/well and cultured
for 30 min. The wells were washed twice with PBS to
remove unattached cells 100 μl 25% rose Bengal solution
was added, incubated for 5 min, the supernatant was
aspirated, the wells were washed twice with PBS. 200 μl
95% ethanol/PBS (1:1) was added, incubated for 20 min
and absorbance was measured at 540 nm. Each assay was
performed in triplicate.
Murine xenograft model
Male 4 to 6 week old BALB/c athymic nude mice were
subcutaneously injected with 2 × 10
6 U251, U251-EV or
U251-SLC22A18 cells. Tumor diameters were measured
at regular intervals with digital calipers, and the tumor
volume in mm
3 was calculated using the formula:
volume = (width)
2 × length/2. The animal experiments
i nt h i ss t u d yw e r ep e r f o r m ed in compliance with the
guidelines of the Institute for Medical School Institutes
at Wuhan University and Shanghai Jiao Tong University.
Immunohistochemical staining
The excised tumors were paraffin-embedded and 4 μM
sections were prepared. Antigen retrieval was performed
by boiling in citrate buffer for 15 min and peroxidase
activity was blocked using 0.3% peroxide in absolute
methanol. The sections were incubated with anti-
SLC22A18 polyclonal antibody (1:100; Sigma) at 4°C
overnight, washed twice with PBS and incubated with
secondary antibody (Santa Cruz, CA) at room tempera-
ture for 30 min. After washing, the sections were incu-
bated with immunoglobulins conjugated with horseradish
peroxidase, staining was visualized using 3, 3’-diamino-
benzidine and the sections were calculated from the total
number of cells observed in least 10 randomly chosen
non-overlapping high-power (×400) fields in each case.
SLC22A18 expression was graded on a scale from + to +
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50% graded ++ and > 50% graded +++.
DNA extraction and MSP
Briefly, genomic DNA was extracted from tumor tissues,
the corresponding normal brain tissues and the U251 cells
by the digestion with proteinase K using the Genomic
DNA Purification Kit (Gentra Systems, Minneapolis, MN,
USA) and 1 μg genomic DNA was treated with the Che-
micon CpG WIZ™ DNA Modification Kit (Chemicon
International, Temecula, CA, USA) to convert unmethy-
lated cytosines to uracil, leaving methylated cytosines
unchanged. The modified DNA was diluted in TE buffer.
SLC22A18 promoter methylation analysis was performed
by PCR, using bisulfite-treated DNA as template, with spe-
cific primers for the methylated (unmodified by bisulfite
treatment) and unmethylated (bisulfite modified) gene
sequences using the MSP method [16]. The SLC22A18
primer sequences for the unmethylated reaction (UMS
sense 5’-CGTTTTTGTAAAGGTAGGTATTCGA-3’ and
UMAS antisense 5’-AAACTAAAAAAAACAAAACAA
CCG-3’) were designed to amplify a 144 bp product [16].
The SLC22A18 primer sequences for the methylated reac-
tion (MS sense 5’-CGTTTTTGTAAAGGTAGGTATT
CGA-3’ and MAS antisense 5’-AACTAAAAA AAA-
CAAAACAACCACA-3’) were designed to amplify a
146 bp product [16]. The results were confirmed by
repeating the bisulfite treatment and MSP assays for all
samples.
Total RNA isolation and reverse-transcriptase polymerase
chain reaction
Total RNA was extracted from glioma tissues, the adjacent
brain tissues, the glioma cell line U251, astrocytes, oligo-
dendrocytes and neurons using TRIzol (Invitrogen, Carls-
bad, CA) following the manufacturer’s instructions. The RT
reaction was performed on 2 μgo ft o t a lR N Au s i n gt h e
SuperScript II First-Strand Synthesis and an oligo(dT) pri-
mer (Invitrogen). The SLC22A18 primer sequences and
RT-PCR conditions were as previously described (forward
primer 5’-GCTTCGGCGTCGGAGTCAT-3’ and reverse
primer 5’-AGCCTGGGCGTCAGTTTT-3’) [16]. The
housekeeping gene GAPDH was used as an internal control
for the RT reaction (forward primer 5’-GGGAGCCAAA
AGGGTCATCATCTC-3’ and reverse primer 5’-CCATG
CCAGTGAGCTTCCCGTTC-3’) [16]. PCR was performed
over 35 cycles at 94°C for 1 min, at 62°C for 1 min, and
72°C for 1 min followed by a final extension at 72°C for
5 min and the PCR products were analyzed using 2% agar-
ose gels.
Western blotting
Untransfected U251 cells, U251-EV, U251-SLC22A18
cells, 5-aza-2-deoxycytidine-treated cells, astrocytes,
oligodendrocytes and neurons were washed in ice-cold
PBS and lysed in buffer using standard methods [17].
Brain tissues were homogenized using a homogenizer in
RIPA lysis buffer (50 mM Tris-HCl, pH 8.0, 1% NP40,
0.1% SDS, 100 μg/ml phenylmethylsulfonyl fluoride,
0.5% sodium deoxycholate, 0.02% sodium azide, 1 μg/ml
aprotinin and 150 Mm NaCl) on ice. The supernatants
were collected after centrifugation at 14,000 × g at 4°C
for 10 min, protein concentration was determined and
whole-tissue lysates were mixed with an equal amount
5X SDS loading buffer (125 mM Tris-HCl, 4% SDS, 20%
glycerol, 100 mM DTT and 0.2% bromophenol blue) as
previously described [18]. Samples were heated at 100°C
for 5-10 min and were separated on pre-cast 10% SDS-
polyacrylamide gels (Fluka, Ronkonkoma, NY, USA),
electrotransferred onto nitrocellulose membranes (Invi-
trogen) blocked for 1 h at room temperature in 5% non-
fat milk in TBS (20 mM Tris-HCl, 150 mM NaCl and
0.1% Tween-20), incubated overnight at 4°C with anti-
SLC22A18 antibody (1:1,000), then with a horseradish
peroxidase-conjugated secondary antibody (1:5,000) for
1 h at room temperature in 1% non-fat milk in TBS and
the bands were visualized using the enhanced chemilu-
minescence system (Pierce, Rockford, IL, USA).
Data analysis
Statistical differences between groups were examined
using the Fisher’se x a c tt e s t .P-values less than 0.05
were considered statistically significant.
Results
SLC22A18 protein expression is downregulated in glioma
We examined the expression of SLC22A18 gene in 60
gliomas and the adjacent normal brain tissues using
immunohistochemistry. In the adjacent normal brain tis-
sue, brown positive staining was mostly homogeneously
distributed within the cytoplasm (Figure 1A). In glioma
tissues, SLC22A18 was expressed at reduced levels com-
pared to normal tissue (Figure 1B). Semi-quantitative
analysis indicated a significant reduction in SLC22A18
expression in gliomas and the corresponding adjacent
brain tissue (P = 0.000, Figure 1C).
Downregulation of SLC22A18 protein expression is
associated with malignancy in glioma
To evaluate the correlation between the SLC22A18 expres-
sion and the biological characteristics of glioma, SLC22A18
protein expression was compared in 30 patients with high
grade (WHO III-IV) glioma and another 30 patients with
low grade (WHO I-II) gliomas. SLC22A18 expression was
significantly lower in the high grade gliomas than low
grade gliomas (P =0 . 0 1 8 ,F i g u r e2 A ) .SLC22A18 expression
in the 14 glioma specimens obtained from patients with
recurrences six months after surgery was significantly
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recurrences six months after surgery (P =0 . 0 0 2 ,F i g u r e2 B ) .
Aberrant promoter methylation contributes to SLC22A18
downregulation
To explore whether aberrant promoter methylation was
responsible for the downregulation of SLC22A18 in
glioma tissues, the methylation status of the SLC22A18
promoter and SLC22A18 expression were correlated in
the 30 glioma specimens and the corresponding normal
tissues. Promoter methylation occurred in gliomas from
15/30 patients and was absent in all of the adjacent
brain tissues (Figure 3A). The SLC22A18 methylation
status and clinicopathological characteristics of all 30
glioma patients are shown in Table 1. RT-PCR analysis
indicated that SLC22A18 mRNA was significantly
decreased or absent in all of the 15 gliomas in which
the SLC22A18 promoter was methylated, compared to
adjacent normal brain tissues (Figure 3B). Furthermore,
Western blotting analysis demonstrated that in the 15/
30 glioma samples with SLC22A18 promoter methyla-
tion, SLC22A18 protein expression was significantly
decreased compared to the adjacent normal brain tissue
(Figure 3C). Semiquantitative analysis of immunohisto-
chemical staining indicated that SLC22A18 expression
in the 15 glioma samples with promoter methylation
was significantly lower than the other 15 glioma samples
without promoter methylation (P = 0.033, Figure 4).
This findings suggesting that promoter methylation
contributes to SLC22A18 regulation in gliomas.
Figure 1 SLC22A18 is downregulated in glioma.R e p r e s e n t a t i v e
images of SLC22A18 immunohistochemical staining in (A) adjacent
normal brain tissue and (B) glioma, × 200. (C) Semiquantitative
analysis of SLC22A18 expression in glioma and the adjacent brain
tissue, P value compares overall SLC22A18 expression in each group.
Figure 2 SLC22A18 expression in patients stratified by tumor
grade and recurrence. (A) Semiquantitative analysis of SLC22A18
immunohistochemical staining in low grade (WHO I-II) glioma and
high grade (WHO III-IV) glioma. (B) Semiquantitative analysis of
SLC22A18 immunohistochemical staining in gliomas which recurred
and those which did not recur within six months after surgery,
P values compare overall SLC22A18 expression in each group.
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promoter methylation, 10/15 recurred within six months
after surgery, indicating that SLC22A18 promoter
methylation and protein downregulation is associated
with glioma recurrence. However, compared to normal
tissues, SLC22A18 mRNA and protein expression were
downregulated in 26 of the 30 glioma samples tested,
yet SLC22A18 promoter methylation was only observed
in 15/30 of these gliomas. This data demonstrates that
promoter methylation is involved in the downregulation
of SLC22A18 in gliomas, but that other mechanisms
also regulate SLC22A18 expression.
Promoter demethylation increases SLC22A18 expression
and reduces U251 cell growth
We observed that the SLC22A18 promoter is methylated
in the human glioma cell line U251 (Figure 3A). To study
whether demethylation agents can restore SLC22A18
expression, the cells were treated with the demethylation
agent 5-aza-2-deoxycytidine (2 μM) for 9 days and the
cell number was determined on days 3, 5 and 7. Western
blotting demonstrated that SLC22A18 expression in
5-aza-2-deoxycytidine-treated cells increased significantly
compared to untreated control cells (Figure 5A). More-
over, increased SLC22A18 expression was associated
with a decreased rate of cell growth following 5-aza-2-
deoxycytidine treatment (P < 0.05, Figure 5B).
PCR analysis of SLC22A18 in U251 cells
A SLC22A18 stable cell line was generated by transfection
of U251 cells with SLC22A18 cDNA and stable clones
were selected using G148. DNA was extracted from
untransfected U251, U251-EV and U251-SLC22A18 cells
and subjected to PCR using a primer pair designed to
Figure 3 Correlation between SLC22A18 promoter methylation and SLC22A18 mRNA and protein expression.( A )SLC22A18 promoter
methylation analysis. In patients 1, 8, 15 and 30, the SLC22A18 promoter was methylated in glioma and not the adjacent brain tissue. The
SLC22A18 promoter is also methylated in U251 cells. T, glioma; N, adjacent brain tissue; m, methylated; u, unmethylated. (B) SLC22A18 RT-PCR
mRNA expression in patients 1, 8, 15 and 30. GAPDH was used as an internal control. (C) Western blot of SLC22A18 protein expression in patients
1, 8, 15 and 30. ß-actin was used as an internal control. Both SLC22A18 mRNA and protein expression are significantly downregulated in gliomas
with promoter methylation, compared to the corresponding adjacent normal brain tissues.
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U251-SLC22A18 cells, but not in untransfected U251 or
empty plasmid transfected U251-EV cells (Figure 6), con-
firming the stable expression of SLC22A18 in U251-
SLC22A18 cells.
SLC22A18 protein is expressed in U251-SLC22A18 cells
Total protein was exacted from untransfected U251,
U251-EV and U251-SLC22A18 cells and analyzed by
Western blotting. A 50 kDa band corresponding to the
expected size of SLC22A18 was observed in U251-
SLC22A18 cells, but not in U251-EV or U251 cells
(Figure 7).
Cell proliferation assay
As shown in Figure 8, U251-SLC22A18 caused a statis-
tically significant reduction of cell viability to (31.5 ±

















1 5 3 M 3 . 5×4×3 + I V + 4 3 3
3 42 M 3 × 4.5 × 5 + III + 25 58
8 38 F 3.5 × 3 × 3 + III + 35 62
9 4 9 M 3×4×3 + I V + 3 4 2
10 58 M 5.5 × 4 × 4 - II + 39 67
15 69 M 3.5 × 4 × 3 + IV + 8 38
17 32 M 5 × 6 × 4 - II + 37 65
19 45 F 4 × 5 × 6 - II + 34 59
20 51 M 4.5 × 5 × 6 + IV + 0 25
21 43 M 3.5 × 4 × 5 + IV + 9 35
24 48 M 3.5 × 4 × 4 - II + 32 61
25 55 F 3.5 × 4 × 5 - II + 30 59
27 62 F 4 × 4 × 3 + IV + 0 30
29 34 M 5 × 4 × 3 - II + 37 65
30 39 M 3.5 × 2 × 3 + IV + 6 38
2 7 1 M 2×3×4 - I - 4 5 6 8
4 3 3 M 3×4×5 - I I - 3 2 6 1
5 4 3 M 3×4×6 - I - 4 6 6 2
6 46 F 3.5 × 4 × 4 + III - 25 57
7 48 M 4.5 × 4 × 5 - II - 37 68
11 47 F 5.5 × 5 × 6 + IV - 12 54
12 57 M 5 × 6 × 5 - II - 32 70
13 56 M 3.5 × 5 × 6 - I - 52 75
14 46 M 3.5 × 5 × 4 - I - 45 72
16 57 M 3 × 3 × 4 + IV - 14 62
18 53 M 3 × 4 × 5 - I - 52 78
22 54 F 5.5 × 6 × 5 - I - 48 73
23 65 M 3 × 4 × 3 + III - 34 65
26 46 F 3.5 × 5 × 4 - I - 52 82
28 62 M 3 × 4.5 × 5 + III - 29 62
Figure 4 Semiquantitative analysis of SLC22A18 protein
expression in gliomas with and without SLC22A18 promoter
methylation. P-value compares overall SLC22A18 expression in each
group.
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such change.
Induction of apoptosis by the SLC22A18 expression
Cells were examined for apoptosis induction by FCM.
As shown in Table 2, U251-SLC22A18 induced signifi-
cant apoptotic response after transfection, about 25.25 ±
4.28 for 24 hours and 30.84 ± 4.72 for 48 hours. How-
ever, U251 and U251-EV did not induce any significant
apoptotic response until 48 hours after transfection.
Effects of SLC22A18 expression on U251 cell adhesion
Upregulated SLC22A18 expression had a clear inhibitory
effect on the adhesion of transfected U251 cells to the
extracellular matrix (ECM) [Matrigel and Fn] and to
ECV304. The percentages of adhesion to ECM were as
follows: U251, (39.2 ± 2.21)% (Fn) and (89.4 ± 1.52)%
(Matrigel); U251-EV, (38.6 ± 3.18)% (Fn) and (88.6 ±
1.54)% (Matrigel); U251-SLC22A18, (8.5 ± 3.16)% (Fn)
and (38.2 ± 1.57)% (Matrigel) (Figure 9A). The tumor cell
lines showed different absorbance abilities: U251, 0.592 ±
0.008; U251-EV, 0.589 ± 0.015; U251-SLC22A18, 0.264 ±
0.012 (Figure 9B). Thus, the adhesion of U251-
SLC22A18 to ECM and to ECV304 cells was significantly
suppressed.
Effects of SLC22A18 expression on tumor growth in vivo
As shown in Figure 10, U251 and U251-EV xenograft
tumors formed and grew rapidly. In contrast, U251-
SLC22A18 xenograft tumor formation was significantly
Figure 5 The demethylating agent 5-aza-2-deoxycytidine restores
SLC22A18 expression in U251 cells and suppresses cell growth.
(A) Western blotting indicating a significant increase in SLC22A18
expression after treatment of U251 cells with 2 μg/ml 5-aza-2-
deoxycytidine for 7 days: 1, control cells; 2, treated cells; ß-actin was
used as an internal control. (B) Growth curves demonstrating reduced
cell numbers in the 5-aza-2-deoxycytidine-treated group, compared to
empty plasmid transfected U251-EV cells and untransfected U251 cells.
Figure 6 PCR amplification of SLC22A18 in U251-SLC22A18
stable cell lines. M, DNA molecular mass marker; lane 1, culture
medium only control; lane 2, empty plasmid transfected U251-EV
cells; lane 3, untransfected U251 cells; lane 4, U251-SLC22A18 cells.
Figure 7 Western blot of SLC22A18 protein expression in U251-
SLC22A18 stable cell lines. Lane 1, U251-SLC22A18 cells; lane 2,
empty plasmid transfected U251-EV cells; lane 3, untransfected U251
cells. b-actin was used as loading control.
Chu et al. Journal of Translational Medicine 2011, 9:156
http://www.translational-medicine.com/content/9/1/156
Page 8 of 13delayed. At the end of the experiment, the U251-
SLC22A18 tumors were significantly smaller than the
tumors from untransfected U251 and U251-EV negative
control cells.
Expression of SLC22A18 in normal neurons, astrocytes
and oligodendrocytes
We analyzed the expression of SLC22A18 mRNA and
protein in normal neurons, astrocytes and oligodendro-
cytes. Neurons expressed both SLC22A18 mRNA and
protein, while astrocytes and oligodendrocytes did not
express either SLC22A18 mRNA or protein (Figure 11).
Expression of SLC22A18 in adult mouse brain
To identify the cells which express SLC22A18, we per-
formed SLC22A18 immunostaining on sections of adult
mouse brain. Strong SLC22A18 immunostaining was
observed in the cortex and cerebellum, but little reactivity
was detected in the brainstem. Representative examples of
SLC22A18 immunostaining are shown in Figure 12. Hippo-
campal neurons in all regions (Figure 12A-C) showed
strong staining. In the olfactory bulb (Figure 12D-F), mitral
cells demonstrated the strongest immunostaining (Figure
12E). Weaker SLC22A18 staining in periglomerular cells
(Figure 12F) and very sparse staining in the internal and
external plexiform layers was observed. Purkinje cells in the
cerebellum (Figure 12G-I) were strongly SLC22A18 posi-
tive. The scant cytoplasm of the neurons in the internal
granular layer was SLC22A18 positive, while only stellate
and basket interneurons were weakly positive in the mole-
cular layer. No staining of dendrites was evident in the
molecular layer. SLC22A18 expression was not detected in
the white matter tracts of the cerebellum (Figure 12J) even
though staining of sequential sections showed the presence
of GFAP-positive astrocytes (Figure 12L) and GalC-positive
oligodendrocytes (data not shown). Detailed examination of
the corpus callosum (Figure 12K) did not reveal SLC22A18
Figure 8 Cytotoxic effect of SLC22A18 expression in U251 cells.
U251-SLC22A18, empty plasmid transfected U251-EV cells and
untransfected U251 cells were cultured in plastic 96-well plates and
quantified using the MTT assay.
Table 2 Mean ± SEM apoptotic rate (percentage) in
SLC22A18 transfected U251 cells
Group (n = 6) 24 h 48 h
Normal U251 1.95 ± 0.32 3.69 ± 0.19
U251-EV 1.95 ± 0.38 3.71 ± 0.21
U251-SLC22A18 25.25 ± 4.28 30.84 ± 4.72
Figure 9 Effects of SLC22A18 expression on U251 cell adhesion.
(A) U251 cell adhesion to ECM (Fn and Matrigel). (B) U251 cell
adhesion to ECV304.
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Page 9 of 13expression in glial cells. Neurons of the amygdala (Figure
12K) were also SLC22A18 positive.
Discussion
Studies of the underlying molecular mechanisms involved
in glioma formation and progression provide tremendous
opportunities to identify molecules which may provide
novel potential drug design targets for the treatment of
brain tumors. Mutations and overexpression of several
oncogenes, including c-Met, PDGF and c-myc, have been
identified in glioma patients [4,19]. Using molecular analy-
sis, loss of heterozygosity has been observed on several
chromosomes in patients with glioma. Many of these
chromosomal segments contain known tumor suppressor
genes [20,21], such as p16 on 9p, p53 on 17p and RB on
13q. SLC22A18, also known as IMPT1/BWR1A/TSSC5,i s
located in the 11p15.5 region and encodes an efflux trans-
porter-like protein with 10 transmembrane domains,
whose expression can affect cellular metabolism, cellular
growth and drug sensitivity [7]. Human chromosome
11p15.5 is frequently lost in a variety of tumors, including
Wilms’ tumor, lung cancer, in hepatocarcinoma cells [6]
a n da l s oi nb r e a s tc a n c e r ,s u g g e s t i n gt h a to n eo rm o r e
tumor suppressor genes map to this region [5]. Exonic
deletions of 11p15.5 in Wilms’ tumors [5] and loss of het-
erozygosity in hepatoblastomas [8] have also been
reported, indicating that SLC22A18 m a yp l a yar o l ei n
tumorigenesis; however, SLC22A18 expression in glioma
Figure 10 Effects of SLC22A18 expression on tumor growth in vivo. (A) Subcutaneous tumor model. a, U251 cells group; b, U251-EV cells
group; c, U251-SLC22A18 cells group. (B) Tumor growth curves of each group over 28 days.
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viously been investigated in humans.
In our study, we demonstrated that SLC22A18 protein
expression was significantly decreased in gliomas com-
pared to the adjacent brain tissues. We observed that
normal neuron express SLC22A18 mRNA and protein,
but normal astrocytes and oligodendrocytes do not. The
lack of detectable SLC22A18 expression in human astro-
cytes and human oligodendrocytes raises the intriguing
question of how SLC22A18 can influence development
of glial tumors. The critical point in developing such a
scheme is the identity of the glioma progenitor cell.
Although older models proposed that gliomas result
from dedifferentiated astrocytes, it recently has been
suggested that gliomas are transformed glial precursor
cells [22,23]. Recently the discovery that oligodendrocyte
precursor cells (OPCs) are the point of origin was
reported [24]. Hence, important questions for future
studies include whether glial precursor cells in vitro and
in vivo are SLC22A18 positive and whether loss of
SLC22A18, perhaps combined with other genetic lesions,
initiates excess cell proliferation. The availability of
mouse models will provide answers to these questions
as well as an experimental system to develop new thera-
peutic approaches for gliomas. We also showed that
decreased expression of SLC22A18 was correlated with
an increased post-operative recurrence of glioma,
suggesting that downregulation of SLC22A18 can affect
the degree of malignancy in glioma. Aberrant methyla-
tion of the SLC22A18 promoter is one major mechan-
ism responsible for the inactivation or downregulation
of SLC22A18 in a number of tumor types, including
breast [6], lung [5] and hepatoblastomas [8]. Our study
indicates that aberrant methylation of the SLC22A18
promoter occurred in 15 of the 30 gliomas tested, which
correlated with significantly reduced SLC22A18 mRNA
and protein expression suggesting that aberrant promo-
ter methylation contributes to decreased SLC22A18
expression in glioma. Of the 15 patients whose gliomas
had SLC22A18 promoter methylation, 10 recurred
within six months after surgery; while only 5 of the 15
without promoter methylation recurred within six
months after surgery. Our findings demonstrate that
promoter methylation is involved in SLC22A18 downre-
gulation in glioma; however, other mechanisms are
involved in SLC22A18 regulation. It is possible that
other epigenetic modifications, such as histone acetyla-
tion, may modulate changes in SLC22A18 gene expres-
sion [25]. Some researchers have reported that dual
promoters, P1 and P2, exist for the SLC22A18 gene. Sp1
is a transactivator of the P1 promoter, suggesting that
DMR may not be associated with the SLC22A18 promo-
ters or CpG II islands. The SLC22A18 expression was
previously reported to be methylation-dependent and
histone acetylation-independent [26]. The core
SLC22A18 promoter lies in the region -120 bp to +78
bp and is devoid of TATA or CAAT boxes. SLC22A18
is positively regulated by Sp1 via two functional Sp1
transcription factor binding sites in the promoter region,
which are conserved in the human, chimpanzee, mouse
and rat gene [27].
To determine whether SLC22A18 promoter methyla-
tion contributes to increased glioma growth, U251 cells
were used to study whether a demethylation agent could
restore SLC22A18 expression. The demethylation agent
5-aza-2-deoxycytidine restored SLC22A18 expression in
U251 cells and reduced cell growth. Clearly, as the
development of glioma is closely related to both the
inactivation of several tumor suppressor genes and over-
expression of other genes, overexpression of the single
gene SLC22A18 could not explain all the biological
characteristics of glioma. However, in the present study,
we identified that SLC22A18 overexpression can effec-
tively inhibit the growth and adhesion of U251 glioma
cells, and additionally, overexpression of SLC22A18 can
trigger apoptosis in glioma cells in vitro and delay
tumor growth in vivo.
Conclusions
Collectively, our data demonstrates that SLC22A18 pro-
moter methylation contributes to the downregulation of
Figure 11 SLC22A18 mRNA and protein is expressed in neurons
but not astrocytes or oligodendrocytes in vitro. SLC22A18 RT-PCR
(A) and Western blot (B). Lane 1, neurons; lane 2, astrocytes; lane 3,
oligodendrocytes; M, standard DNA molecular mass marker.
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Page 11 of 13Figure 12 SLC22A18 mRNA and protein is expressed in neurons but not astrocytes or oligodendrocytes in vivo.( A ,B )SLC22A18
immunohistochemical staining in the hippocampus and (C) at high magnification in CA1. (D) Olfactory bulb including glomeruli (Gl), mitral cells
(Mi), and the inner granule layer (IGL). (E) High magnification view of mitral cells. (F) Small SLC22A18-positive periglomerular cells. (G) Cerebellum
showing weak staining of the internal granule layer (IGL), strong staining of Purkinje cells (P) and occasional positive cells in the molecular layer
(ML). No staining of dendrites was evident in the ML. (H) High magnification of Purkinje cells. (I) High magnification of the IGL, showing
cytoplasmic SLC22A18 staining. (J) White matter tracts in the cerebellum indicated by *. (K) Corpus callosum indicated by * with SLC22A18-
positive amygdala (Am) observed at the right edge. (L) High magnification of a double stained astrocytic cell (SLC22A18, red brown; GFAP, blue
gray) in white matter tracts of the cerebellum. All sections were counterstained with methyl green, scale bars = 20 μm.
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Page 12 of 13SLC22A18 in gliomas and reduced SLC22A18 expression
plays a role in the molecular pathogenesis of glioma, as
SLC22A18 overexpression can effectively inhibit U251
glioma cell growth and adhesion in vitro and tumor
growth in vivo.
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